Grant Program

Overview of Grant Program

The Pharmacotherapies for Alcohol and Substance Use Disorder Alliance (PASA) is funded by the Congressionally Directed Medical Research Programs (CDMRP) as part of its Alcohol and Substance Use Disorder Research Program (ASUDRP). 

The goal of the PASA is to fund research for developing new medications that can improve treatment outcomes for alcohol and substance use disorders (ASUD); especially as related to post-traumatic stress disorder (PTSD) and other psychological disorders.  Research proposed can be for an alcohol use disorder (AUD), substance use disorder (SUD), or both an AUD and SUD.

The exact number and type of studies approved during each solicitation period will depend on the quantity and quality of applications received and amount of available funding.

Current Funding Opportunities

This PASA Request for Application (RFA) #6 cycle includes has three aims:  

  • Aim 1: Discover: Test new chemical entities and repurpose existing medications in strictly pre-clinical and non-clinical models of ASUD with comorbid PTSD and other psychological disorders.

  • Aim 2: Phase 1 First-in-Human Safety: Conduct clinical trials of potential medications that include assessment of medical safety and doses for potential efficacy in subjects with ASUD and comorbid PTSD and other psychological disorders.

  • Aim 3: Phase 2 Efficacy: Conduct multiple site clinical trials to test preliminary efficacy and safety of potential medications or medication combinations in humans with ASUD and comorbid PTSD and other psychological disorders, and to also explore precision medicine tools for matching patients to these medications.

    • RFA 6a/Planning Grant:
      • Small-cost and short-duration planning grant concerning a specific compound or combination of compounds; to determine the clinical development plan and associated clinical trial(s) needed to advance the compound (or combination of compounds) to FDA approval for ASUD treatment.
      • For this RFA (6a/Planning Grant):
        • Soliciting for planning grants under Aims 2 and 3 human participant clinical trials.
      •  Timeline:
        • Letter of Intent: 27-May-22
        • Full Application Deadline: 08-Jul-22
    • RFA 6b/Pre-Clinical:
      • Full study implementation awards for proof-of-principle pre-clinical animal research to determine which compounds are most appropriate for human research trials. Using animal models, medications will be assessed to determine if they reduce the aberrant behaviors in models of ASUD comorbid with PTSD or other psychological disorders and potential dosages of these medications can then be estimated for human studies.
      • For this RFA (6b/Pre-Clinical):
        • ​​Soliciting for research grants under Aim 1 pre-clinical animal research studies.
      • Timeline:
        • Letter of Intent: 27-May-22
        • Full Application Deadline: 22-Jul-22
    • RFA 6c/Non-Clinical:
      • Full study implementation awards for proof-of-principle non-clinical research to identify a pool of compounds most appropriate for additional research. The non-clinical research is intended to increase the potential pool of compounds for investigation in subsequent pre-clinical studies and clinical trials. Approaches to identifying promising compounds for development or repurposing studies that leverage large-scale data through computational-based analysis include but are not limited to in silico and augmented intelligence research.
      • For this RFA (6c/Non-Clinical):
        • Soliciting for research grants under Aim 1 non-clinical research studies focused on ASUD comorbid with PTSD and other psychological disorders
      • Timeline:
        • Letter of Intent: 27-May-22
        • Full Application Deadline: 22-Jul-22

The LOIs are largely for planning purposes; no response from PASA is required to proceed with the full application.

Links for downloading the RFAs are provided below.

Documents